Pharmacokinetics and pharmacodynamics of anticoagulants in paediatric patients

Area of Science:

• Pharmacology
• Paediatric Medicine
• Haemostasis

Background:

• Rising thrombotic complications in children necessitate understanding anticoagulant drug behavior.
• Developmental variations in haemostasis and drug pharmacokinetics in children present unique challenges.
• Paediatric patients are a vulnerable population requiring specialized pharmacological considerations.

Purpose of the Study:

• To review pharmacologic information for anticoagulant dosing in paediatric patients.
• To highlight age- and weight-based dosing differences for commonly used anticoagulants.
• To identify knowledge gaps and future research priorities in paediatric anticoagulation.

Main Methods:

• Review of existing literature on anticoagulant pharmacokinetics and pharmacodynamics in children.
• Analysis of dosing requirements for unfractionated heparin, low molecular weight heparin, and warfarin.
• Discussion of bivalirudin, argatroban, and fondaparinux in paediatric use.

Main Results:

• Younger paediatric patients often require higher bodyweight-based doses of heparin and warfarin compared to adults.
• These higher doses are likely due to an inverse correlation between age and bodyweight-normalized drug clearance.
• The validity of extrapolating adult therapeutic ranges to paediatric populations remains unknown.

Conclusions:

• Current evidence suggests distinct dosing strategies for paediatric anticoagulation, especially for heparin and warfarin.
• Further research is crucial to establish appropriate therapeutic ranges for children.
• Novel oral anticoagulants require extensive pharmacologic investigation before paediatric use.